News archive
Showing 671 results
April 2021
-
Media ReleaseNovartis Cosentyx® data at AAD VMX shows improvement in skin symptoms and quality of life was maintained up to one year in children with moderate to severe plaque psoriasisAt least 75% of children six years and older achieved PASI 90 at Week 52 when treated with Cosentyx in two pivotal studies1,2 Majority of children experienced improved health-related quality of…
-
Story Education and Awareness
Building clinical trial diversity for long-term equityVas Narasimhan reflects on how to increase diversity in clinical trials
-
Media ReleaseKesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMSKesimpta reduced the risk of disability progression independent of relapse activity (PIRA) by up to almost 60% vs first-line teriflunomide in a subgroup of newly diagnosed, treatment-naïve patients…
-
Media ReleaseNovartis presents data at AAN on novel combination biomarker that may predict disability worsening in secondary progressive multiple sclerosisNew post hoc data from the Phase III EXPAND trial showed combined high levels of plasma neurofilament light chain (NfL) and plasma glial fibrillary acidic protein (GFAP) were consistently…
-
Media ReleaseNovartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients
-
Media ReleaseNovartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patientsXolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment EAST HANOVER, N.J., April 12, 2021…
February 2021
-
Story Education and Awareness
Understanding Heart Health Inequities During Black History MonthAfter years of decline, cardiovascular disease mortality is on the rise, with a disproportionate impact on Black Americans
-
Media ReleaseNovartis Entresto® granted expanded indication in chronic heart failure by FDA
-
Media ReleaseNovartis Entresto® granted expanded indication in chronic heart failure by FDAEntresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (…
-
Story Global Impact
Reimagining Healthcare in Challenging Times: Novartis in Society US Report for 2020Novartis is striving every day to help patients, strengthen communities, drive sustainability and build a more equitable healthcare system for all.